Summary
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K report on April 24, 2003, to disclose its financial results for the quarter ended March 31, 2003. This filing primarily serves as a means to disseminate this important financial information to the public under Regulation FD, ensuring all investors have access to the same material updates simultaneously. Investors should note that this report is distinct from detailed financial statements typically found in a 10-Q filing. Its core purpose is to provide timely notification of the company's performance. While the full press release detailing the results is attached as an exhibit, the 8-K itself functions as the official notification mechanism for these financial outcomes.
Key Highlights
- 1Vertex Pharmaceuticals Inc. filed an 8-K report on April 24, 2003.
- 2The report's primary purpose is to disclose financial results for the quarter ended March 31, 2003.
- 3The information is furnished under Item 9 (Regulation FD Disclosure) to ensure fair and timely dissemination of material non-public information.
- 4A press release detailing the financial results for the quarter is attached as Exhibit 99.1.
- 5This filing does not constitute a formal filing for Section 18 of the Exchange Act or incorporation by reference into other filings, but rather a method of public disclosure.
- 6The company is headquartered in Cambridge, Massachusetts.